PA8654601A1 - Agentes citotoxicos que comprenden taxanos nuevos - Google Patents

Agentes citotoxicos que comprenden taxanos nuevos

Info

Publication number
PA8654601A1
PA8654601A1 PA20058654601A PA8654601A PA8654601A1 PA 8654601 A1 PA8654601 A1 PA 8654601A1 PA 20058654601 A PA20058654601 A PA 20058654601A PA 8654601 A PA8654601 A PA 8654601A PA 8654601 A1 PA8654601 A1 PA 8654601A1
Authority
PA
Panama
Prior art keywords
cytotoxic agents
taxans
therapeutic use
new
understanding new
Prior art date
Application number
PA20058654601A
Other languages
English (en)
Inventor
Michael L Miller
Ravi V J Chari
Erkan Baloglu
Alain Commercon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8654601(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PA8654601A1 publication Critical patent/PA8654601A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS AGENTES CITOTOXICOS Y SU UTILIZACION TERAPEUTICA. MAS ESPECIFICAMENTE, LA INVENCION SE REFIERE A NUEVOS AGENTES CITOTOXICOS QUE COMPRENDEN TAXANOS Y SU UTILIZACION TERAPEUTICA. ESTOS NUEVOS AGENTES CITOTOXICOS TIENEN UTILIZACION TERAPEUTICA COMO RESULTADO DE PROPORCIONAR TAXANOS A UNA POBLACION CELULAR ESPECIFICA DE FORMA DIRIGIDA MEDIANTE ENLACE QUIMICO DEL TAXANO CON EL AGENTE DE UNION A LA CEDULA.
PA20058654601A 2004-12-07 2005-12-06 Agentes citotoxicos que comprenden taxanos nuevos PA8654601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04292899A EP1688415A1 (en) 2004-12-07 2004-12-07 Cytotoxic agents comprising new C-2 modified taxanes

Publications (1)

Publication Number Publication Date
PA8654601A1 true PA8654601A1 (es) 2006-09-08

Family

ID=34931584

Family Applications (2)

Application Number Title Priority Date Filing Date
PA20058654201A PA8654201A1 (es) 2004-12-07 2005-12-01 Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2
PA20058654601A PA8654601A1 (es) 2004-12-07 2005-12-06 Agentes citotoxicos que comprenden taxanos nuevos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PA20058654201A PA8654201A1 (es) 2004-12-07 2005-12-01 Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2

Country Status (12)

Country Link
US (1) US7598290B2 (es)
EP (2) EP1688415A1 (es)
JP (1) JP2008523020A (es)
AR (1) AR051785A1 (es)
AU (1) AU2005313445A1 (es)
CA (1) CA2614574A1 (es)
DO (1) DOP2005000243A (es)
PA (2) PA8654201A1 (es)
PE (1) PE20061063A1 (es)
TW (1) TW200640893A (es)
UY (1) UY29250A1 (es)
WO (1) WO2006061259A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2163256T3 (en) 2001-05-11 2015-12-07 Ludwig Inst For Cancer Res Ltd Specific binding proteins and use thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
KR20080030564A (ko) * 2005-05-12 2008-04-04 태피스트리 파마슈티컬스 인코퍼레이티드 표적 컨쥬게이트에 적합한 분자 구조물
ES2609094T3 (es) 2007-01-25 2017-04-18 Dana-Farber Cancer Institute, Inc. Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
CN101688229B (zh) 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
US9283276B2 (en) 2007-08-14 2016-03-15 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
SG10202005580RA (en) 2010-12-09 2020-07-29 Immunogen Inc Methods for the preparation of charged crosslinkers
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
ATE349438T1 (de) * 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
IT1317731B1 (it) * 2000-01-18 2003-07-15 Indena Spa Tassani semisintetici con attivita' antitumorale ed antiangiogenetica.
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
CN100522955C (zh) * 2002-08-02 2009-08-05 伊缪诺金公司 含有新型强效紫杉烷的细胞毒性剂及其治疗用途
BRPI0511109A (pt) * 2004-05-14 2007-11-27 Immunogen Inc método fácil para sintetizar compostos de baccatin iii

Also Published As

Publication number Publication date
WO2006061259A3 (en) 2007-01-11
CA2614574A1 (en) 2006-06-15
US20070270482A1 (en) 2007-11-22
UY29250A1 (es) 2006-06-30
AR051785A1 (es) 2007-02-07
PA8654201A1 (es) 2006-07-03
PE20061063A1 (es) 2006-11-06
US7598290B2 (en) 2009-10-06
DOP2005000243A (es) 2006-11-30
EP1819687A2 (en) 2007-08-22
JP2008523020A (ja) 2008-07-03
TW200640893A (en) 2006-12-01
AU2005313445A1 (en) 2006-06-15
EP1688415A1 (en) 2006-08-09
WO2006061259A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
PA8654601A1 (es) Agentes citotoxicos que comprenden taxanos nuevos
DOP2005000248A (es) Agentes citotoxicos que comprendentaxanos nuevos.
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
ECSP088298A (es) Modulacion de la expresion del receptor glucocorticoide
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
PA8600601A1 (es) Ligandos de receptores de cannabinoides y sus usos
CR10444A (es) Anticuerpo humanizado de c-kit
CR9312A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
UY33029A (es) Antagonistas de espiro-oxindol de mdm2
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
HN2011003139A (es) Antagonistas de trayectoria de erizo de ftalazina disustituida
PA8778601A1 (es) Inhibidores de la unión entre hdm2 y el proteasoma
ECSP066805A (es) Compuestos silinano como inhibidores de cisteína proteasa
UY36961A (es) Receptores celulares universales programables y métodos para usar los mismos
CR8555A (es) Moduladores de receptores de androgenos
AR114148A2 (es) Composición terapéutica saborizada basada en arcilla
UY29387A1 (es) Imidazoles sustituidos con heterociclilamida.
CR11529A (es) Compuestos de cicloalquiloxi y heterocicloalquilopiridina como moduladores del receptor de h3 de histamina
ATE399532T1 (de) Medizinische seife
CL2011000614A1 (es) Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras.